High Prevalence of Factor V Leiden in Healthy Jordanian Arabs

A. Awidi; M. Shannak; A. Bseiso; M. A. M. Kailani; M. A. Kailani; N. Omar; B. Anshasi; N. Sakarneh

doi:10.1055/s-0037-1614528

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1999; 81(04): 582-584
DOI: 10.1055/s-0037-1614528

Rapid Communication

Schattauer GmbH

High Prevalence of Factor V Leiden in Healthy Jordanian Arabs

A. Awidi

¹From the Department of Medicine, Faculty of Medicine, Jordan University, Amman, Jordan

,

M. Shannak

¹From the Department of Medicine, Faculty of Medicine, Jordan University, Amman, Jordan

,

A. Bseiso

¹From the Department of Medicine, Faculty of Medicine, Jordan University, Amman, Jordan

,

M. A. M. Kailani

¹From the Department of Medicine, Faculty of Medicine, Jordan University, Amman, Jordan

,

M. A. Kailani

¹From the Department of Medicine, Faculty of Medicine, Jordan University, Amman, Jordan

,

N. Omar

¹From the Department of Medicine, Faculty of Medicine, Jordan University, Amman, Jordan

,

B. Anshasi

¹From the Department of Medicine, Faculty of Medicine, Jordan University, Amman, Jordan

,

N. Sakarneh

¹From the Department of Medicine, Faculty of Medicine, Jordan University, Amman, Jordan

› Institutsangaben

Abstract

Summary

The prevalence of APC resistance in healthy Jordanian Arabs was studied. Between October 1996 through September 1997 a total of 400 healthy subjects were studied. There were 212 males and 188 females. APC resistance was studied by functional and DNA methods. There were a total of 52 subjects (13%) who were APC resistant by the functional test. There were 49 subjects (12.25%) who had FV Q⁵⁰⁶ by DNA test. Of these there were 42 heterozygous and 7 homozygous (allele frequency 0.07). None of the subjects had clinical thrombosis. It is concluded that the prevalence of APC resistance due to FV Q⁵⁰⁶ is high in Jordanian Arabs.

Volltext

Referenzen

References
1 Dahlbäck B. Inherited thrombophilia: Resistance to protein C as a pathogenic factor of venous thromboembolism. Blood 1995; 85: 607-14.
2 Dahlbäck B. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg 506 to GLn mutation in factor V as a pathogenic risk factor for venous thrombosis. Thromb Haemost 1995; 74: 139-48.
3 Bertina RM, Keoleman BPC, Koster T, Rosendaal FR, Dirven RH, de Ronde H, vander Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
4 Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. E Engl J Med 1994; 330: 517-21.
5 Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-8.
6 Rees DC. The population genetics of factor V Leiden (Arg 506 Gln). Br J Haematol 1996; 95: 579-86.
7 Lee DH, Henderson PA, Blajchman MA. Prevalence of factor V Leiden in a Canadian blood donor population. Can Med Assoc J 1996; 153: 285-9.
8 Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. JAMA 1997; 277: 1305-7.
9 Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4.
10 Takamiya O, Ishida F, Kodaira H, Kifano K. APC-resistance and MnLI genotype (Gln 506) of coagulation factor V are rare in Japanese population (Letter). Thromb Haemost 1995; 74: 996
11 Ozbeck U, Tangun Y. Frequency of factor V Leiden (Arg 506 Gln) in Turkey (Letter). Br J Haematol 1997; 97: 504-5.
12 Dzimiri N, Meyer B. World distribution of factor V Leiden. (Letter). Lancet 1996; 347: 481-2.
13 Hammoud DF, Eldibanny MM, Nowak JA. Prevalence of the factor V leiden mutation in the egyptian population. (Abstract). Blood 1996; 88 (10) (Suppl. 01) (Suppl) 73b.
14 Seligsohn U, Zivelin A. Thrombophilia as a multigenic disorder. Thromb Haemost 1997; 78 (Suppl. 01) 297-301.
15 Awidi A. Congenital hemorrhagic disorders in Jordan. Thromb Haemost 1984; 51: 331-3.
16 Awidi AS, Abu-Khalaf M, Herzallah U, Abu-Rajab A, Shannak MM, Abu-Obeid T, Al-Taher I, Anshasi B. Hereditary thrombophilia among 217 consecutive patients with thromboembolic disease in Jordan. Am J Hematol 1993; 44: 95-100.
17 Kawasaki ES. Sample preparation from blood, cells and other fluids in: PCR protocols, A guide to methods and applications. Innis MA, Gelfand DH, Shinsky JJ, While TJ. eds. San Diego, Academic Press Inc 1990; 146
18 Bowen DJ, Bowley D, John M, Collins PW. Factor V Leiden (G 1691A), the prothrombin 3’ – untranslated region variant (G 20210 A) and thermolabile methylene tetrahydrofolate reductase (C 677 T): A single genetic test genotypes all three Loci-determination of frequencies in the S. Wales population of U.K. Thromb Haemost 1998; 79: 949-54.
19 Ehrenforth S, Zwinge B, Scharrer I. High prevalence of factor V R 506 Q mutation in German thrombophilic and normal population. Thromb Haemost 1998; 79: 684-5.
20 Vanegas OC, Giusti B, Fernandez MR, Abbate R, Pepe G. Frequency of factor V (FV) Leiden and C 677 T methylene-tetrahydrofolate reductase (MTHFR) mutations in Colombians. Thromb Haemost 1998; 79: 883-4.
21 Castoldi E, Lunghi B, Mingozzi F, Ioannou P, Marchetti G, Bernardi F. New coagulation factor V gene polymorphisms define a single and infrequent haplotype underlying the factor V Leiden mutation in mediterranean populations and indians. Thromb Haemost 1997; 78: 1037-41.
22 Pepe G, Rickards O, Vanegas OC, Brunelli T, Gori AM, Giusti B, Attanasio M, Prisco D, Gensini GF, Abbate R. Prevalence of factor V Leiden mutation in non-european populations. Thromb Haemost 1997; 77: 329-31.
23 Chaida C, Gialeraki A, Tsoukala A, Maudalaki A. FVQ⁵⁰⁶ in patients with thrombosis in Greece. (Abstract). Thromb Haemost 1997; 77 (06) (Suppl) 224.
24 Lindqvist PG, Svensson PJ, Dahlbäck B, Marsal K. Factor V Q⁵⁰⁶ mutation (activated protein C resistance) associated with reduced intrapartum blood loss – a possible evolutionary selection mechanism. Thromb Haemost 1998; 79: 69-73.
25 Zivelin A, Yakar S, Brenner B, Eldor A, Rosenberg N, Seligsohn U. Haplotype analysis of factor V gene in Arabs and jews suggests that the Arg 506 GLn mutation causing resistance to activated protein C evolved from common ancestor. (Abstract). Br J Haematol 1996; 93 (Suppl. 02) (Suppl) 6-7.
26 Zivelin A, Griffin JH, Xu X, Pabinger I, Samama M, Conard J, Brenner B, Eldor A, Seligsohn U. A single genetic origin for a common caucasian risk factor for venous thrombosis. Blood 1997; 89 (02) 397-402.